Inogen, Inc. (NASDAQ:INGN) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its position in Inogen, Inc. (NASDAQ:INGN) by 23.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 126,461 shares of the medical technology company’s stock after purchasing an additional 24,082 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.53% of Inogen worth $1,160,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Ieq Capital LLC acquired a new stake in Inogen in the fourth quarter valued at $94,000. JPMorgan Chase & Co. raised its position in shares of Inogen by 2.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 896,106 shares of the medical technology company’s stock worth $8,692,000 after acquiring an additional 23,891 shares in the last quarter. Franklin Resources Inc. purchased a new stake in Inogen during the third quarter worth approximately $139,000. Virtu Financial LLC acquired a new position in Inogen in the third quarter valued at approximately $111,000. Finally, Barclays PLC increased its stake in Inogen by 72.9% in the third quarter. Barclays PLC now owns 55,508 shares of the medical technology company’s stock valued at $539,000 after purchasing an additional 23,398 shares during the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

INGN has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a research report on Wednesday, February 26th. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th.

Inogen Price Performance

INGN stock opened at $7.37 on Tuesday. Inogen, Inc. has a 12 month low of $6.14 and a 12 month high of $13.33. The company has a market cap of $195.53 million, a price-to-earnings ratio of -3.28 and a beta of 1.15. The company has a fifty day moving average price of $9.69 and a 200 day moving average price of $9.64.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.